Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta + tislelizumab + chemotherapy as neoadjuvant therapy for locally advanced nasopharyngeal carcinoma
ChiCTR2500110359Phase 2Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Foshan First People's Hospital. Primary endpoint: Complete Response Rate after neoadjuvant therapy. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cetuximabtislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500110359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110359.